Development and production aspects of a recombinant yeast-derived hepatitis B vaccine.
Any attempt to control or eradicate hepatitis B on a global scale requires the availability of large quantities of effective, safe and affordable hepatitis B vaccine. The drawbacks of the first generation of plasma-derived vaccines--poor acceptance, relatively high cost, limited availability--have led to the search for alternative means of producing hepatitis B vaccines. This article reviews the development and production of a yeast-derived vaccine based on recombinant DNA technology and discusses potency, stability and potential availability for use in the implementation of vaccination programmes.
Stephenne
J
J
SmithKline Biologicals, Rixensart, Belgium.
D017325:Hepatitis B Vaccines; D006801:Humans; D012441:Saccharomyces cerevisiae; D014614:Vaccines, Synthetic / Q000276:immunology / Q000302:isolation & purification / Q000600:supply & distribution; D014761:Viral Hepatitis Vaccines / Q000276:immunology / Q000302:isolation & purification* / Q000600:supply & distribution
D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines